| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.067 | 0.03 |
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | -0.074 | 0.03 |
| mRNA | PDMP | CTRPv2 | pan-cancer | AAC | -0.079 | 0.03 |
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | -0.069 | 0.03 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.03 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | -0.065 | 0.04 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.072 | 0.04 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.04 |
| mRNA | Ko-143 | CTRPv2 | pan-cancer | AAC | -0.075 | 0.04 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.074 | 0.04 |